Literature DB >> 11807782

Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.

Ute A Sartorius1, Peter H Krammer.   

Abstract

Chemotherapeutic drugs eliminate cancer cells by induction of apoptosis. Resistance to chemotherapy is partly due to a decreased apoptosis rate. Here we investigated resistance to anticancer drugs in 9 small cell lung cancer (SCLC) cell lines. Apoptosis was induced by cisplatin, doxorubicin and etoposide and was found to be independent of caspase-8 expression. Since caspase-8 is essential for signal transduction of death receptor-mediated apoptosis, all known death receptor systems are thus not required for drug-induced apoptosis in SCLC. Furthermore, we found that anticancer drugs could activate the mitochondrial pathway of apoptosis without involvement of upstream caspases. Finally, by culturing 3 sensitive cell lines in subtherapeutic concentrations of etoposide, resistant cells were generated that exhibit cross-resistance to cisplatin and doxorubicin. Drug resistance was paralleled by strong upregulation of Bcl-2, which diminished apoptosis by inhibiting the loss of the mitochondrial transmembrane potential and the release of cytochrome c. The role of bcl-2 in these processes was supported by bcl-2 transfection and antisense inhibition. These results indicate that Bcl-2 contributes to drug resistance in SCLC, a finding that has profound therapeutic implications. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11807782     DOI: 10.1002/ijc.10096

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  61 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.

Authors:  Terri B Hunter; Neil J Manimala; Kimberly A Luddy; Tracy Catlin; Scott J Antonia
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

Review 3.  Genetics of pancreatic neuroendocrine tumors: implications for the clinic.

Authors:  Antonio Pea; Ralph H Hruban; Laura D Wood
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-28       Impact factor: 3.869

4.  A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.

Authors:  Jung Hun Oh; Joseph O Deasy
Journal:  Brief Bioinform       Date:  2015-07-27       Impact factor: 11.622

5.  Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo.

Authors:  Jason J Zoeller; Aleksandr Vagodny; Krishan Taneja; Benjamin Y Tan; Neil O'Brien; Dennis J Slamon; Deepak Sampath; Joel D Leverson; Roderick T Bronson; Deborah A Dillon; Joan S Brugge
Journal:  Mol Cancer Ther       Date:  2019-04-08       Impact factor: 6.261

6.  Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells.

Authors:  Buntitabhon Sirichanchuen; Thitima Pengsuparp; Pithi Chanvorachote
Journal:  Mol Cell Biochem       Date:  2012-01-26       Impact factor: 3.396

7.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Authors:  Leena Gandhi; D Ross Camidge; Moacyr Ribeiro de Oliveira; Philip Bonomi; David Gandara; Divis Khaira; Christine L Hann; Evelyn M McKeegan; Elizabeth Litvinovich; Philip M Hemken; Caroline Dive; Sari H Enschede; Cathy Nolan; Yi-Lin Chiu; Todd Busman; Hao Xiong; Andrew P Krivoshik; Rod Humerickhouse; Geoffrey I Shapiro; Charles M Rudin
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

8.  P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

Authors:  Zhongyan Hua; Yue Zhan; Simeng Zhang; Yudi Dong; Min Jiang; Fei Tan; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Apoptosis       Date:  2018-08       Impact factor: 4.677

9.  Nicotine enhances the antiapoptotic function of Mcl-1 through phosphorylation.

Authors:  Jinfeng Zhao; Meiguo Xin; Ton Wang; Yangde Zhang; Xingming Deng
Journal:  Mol Cancer Res       Date:  2009-11-10       Impact factor: 5.852

10.  Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis.

Authors:  Srinivas Koduru; Raj Kumar; Sowmyalakshmi Srinivasan; Mark B Evers; Chendil Damodaran
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.